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OBJECTIVES The purpose of this study was to understand the clinical and molecular features of familial
hypertrophic cardiomyopathy (HCM) in which a mitochondrial abnormality was strongly
suspected.
BACKGROUND Defects of the mitochondrial genome are responsible for a heterogeneous group of clinical
disorders, including cardiomyopathy. The majority of pathogenic mutations are heteroplas-
mic, with mutated and wild-type mitochondrial deoxyribonucleic acid (mtDNA) coexisting
within the same cell. Homoplasmic mutations (present in every copy of the genome within
the cell) present a difficult challenge in terms of diagnosis and assigning pathogenicity, as
human mtDNA is highly polymorphic.
METHODS A detailed clinical, histochemical, biochemical, and molecular genetic analysis was performed
on two families with HCM to investigate the underlying mitochondrial defect.
RESULTS Cardiac tissue from an affected child in the presenting family exhibited severe deficiencies of
mitochondrial respiratory chain enzymes, whereas histochemical and biochemical studies of
the skeletal muscle were normal. Mitochondrial DNA sequencing revealed an A4300G
transition in the mitochondrial transfer ribonucleic acid (tRNA)Ile gene, which was shown to
be homoplasmic by polymerase chain reaction/restriction fragment length polymorphism
analysis in all samples from affected individuals and other maternal relatives. In a second
family, previously reported as heteroplasmic for this base substitution, the mutation has
subsequently been shown to be homoplasmic. The pathogenic role for this mutation was
confirmed by high-resolution Northern blot analysis of heart tissue from both families,
revealing very low steady-state levels of the mature mitochondrial tRNAIle.
CONCLUSIONS This report documents, for the first time, that a homoplasmic mitochondrial tRNA mutation
may cause maternally inherited HCM. It highlights the significant contribution that
homoplasmic mitochondrial tRNA substitutions may play in the development of cardiac
disease. A restriction of the biochemical defect to the affected tissue has important
implications for the screening of patients with cardiomyopathy for mitochondrial
disease. (J Am Coll Cardiol 2003;41:1786–96) © 2003 by the American College of
Cardiology Foundation
Over the last decade, mutations in the mitochondrial
deoxyribonucleic acid (mtDNA) have become increasingly
recognized as important causes of disease (1,2), with the
number of different pathogenic defects now described ex-
ceeding 200 (3). Many take the form of mtDNA rearrange-
ments, but an increasing number of maternally inherited
mtDNA point mutations have been described, affecting
protein coding, ribosomal ribonucleic acid (mt-rRNA), or
more commonly, transfer ribonucleic acid (mt-tRNA) genes
(4). Recent epidemiologic studies have estimated the inci-
dence of mtDNA mutations to be at least 1 in 8,000 in a
stable Caucasian population within the Northeast of En-
gland (5). The majority of reported pathogenic mtDNA
mutations are heteroplasmic, a situation in which both the
mutated and wild-type forms of mtDNA are present within
the same cell. Homoplasmic mtDNA mutations (in which
all copies of the genome are affected) have been reported in
association with tissue-specific disease, such as Leber’s
hereditary optic neuropathy (LHON) and sensorineural
hearing loss, affecting protein-encoding (6,7), 12S mt-
rRNA (8), and the mt-tRNASer(UCN) (9–11) genes.
A number of mtDNA point mutations have previously
been described in patients presenting with cardiomyopathy
(12,13). In this report, we describe two families with
hypertrophic cardiomyopathy (HCM) associated with a
homoplasmic A4300G mutation in the mt-tRNAIle gene.
In both families, the clinical features and associated histo-
chemical and biochemical abnormalities were confined to
the heart. We were able to study the cardiac tissue of
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affected individuals from both families, which revealed not
only severely decreased respiratory chain activity but also
very low steady-state levels of mt-tRNAIle.
METHODS
Clinical profile. FAMILY 1. The family tree is reported in
Figure 1A. Patient no. IV-02 was admitted at age 14
months following a five-day history of a sore throat and
swollen glands and a one-day history of lethargy. His
development up to this stage was normal. He was in cardiac
failure with poor peripheral perfusion. An echocardiogram
showed gross dilation of the left ventricle (LV), with grossly
diminished global function (Table 1). The LV was hyper-
trophied. He continued to deteriorate and died of a cardiac
arrest two days after admission. Pathologic examination
revealed marked concentric hypertrophy of the LV, with no
evidence of myocarditis but with hypertrophied myocytes.
The proband (Patient no. IV-03) was carefully monitored
from birth. Left ventricular hypertrophy was noted at 11
months, but LV function was good. He was followed until
the age of five years at regular intervals; clinical examination,
electrocardiography, and echocardiography confirmed
biventricular hypertrophy, but with preserved function. The
child himself was not restricted in his activities. At five
years, he was admitted as an emergency with a four-day
history of lethargy. He was in cardiac failure with very poor
ventricular function (Table 1). His condition rapidly wors-
ened. He died eight days after admission, despite full
supportive therapy. Both surviving boys (Patient nos. IV-01
and IV-04) are asymptomatic. They have evidence of mild
LV hypertrophy (both IV-01 and IV-04) and dilation
(IV-01) based on both clinical and echocardiographic mea-
sures, although neither boy has experienced episodes of
cardiac failure. Their mother and maternal grandmother are
asymptomatic, and the mother has a normal electrocardio-
gram (ECG) and echocardiogram. There is no other history
of cardiomyopathy in the family.
FAMILY 2. The detailed clinical features of this large family
have been reported previously (14,15). Briefly, a diagnosis of
nonobstructive idiopathic HCM was made at 20 years in the
proband (IV-01), who underwent heart transplantation 14
years later for congestive heart failure. A maternal cousin
(IV-09) with LV hypertrophy progressed to congestive
heart failure in six months (Table 1) and is now waiting for
heart transplantation with ventricular mechanical assistance.
Family history was highly suggestive of a maternal pattern
of transmission of the disease (Fig. 1B). All affected mem-
bers, both symptomatic and asymptomatic, had echocardio-
graphic and ECG features of nonobstructive HCM (Tables
1 and 2). Neurological examination was normal.
Cell culture. Fibroblast cultures were obtained by explant
culture of skin biopsy samples from the probands of both
families. Myoblast cultures from the proband of family 1
(IV-03) were obtained as described elsewhere (16). In the
absence of primary skeletal muscle cultures, fibroblasts from
the proband of family 2 (IV-01) and a cousin (IV-03) were
converted to myoblasts using the muscle differentiation
gene, MyoD, as described by Sancho et al. (17). Fibroblasts
were grown in minimal essential medium (MEM) (Life
Technologies, Paisley, United Kingdom) supplemented with
10% fetal calf serum (FCS), 1% MEM nonessential amino
acids, and 1% MEM vitamins. Myoblasts were grown in
Hams F10 (Life Technologies) supplemented with 20% FCS
and 1% chick-embryo extract (ICN Flow Biomedicals, Irvine,
California). In addition, both growth media contained 100
g/ml streptomycin and 100 U/ml benzylpenicillin and were
further supplemented with sodium pyruvate (110 g/ml) and
uridine (50 g/ml) to maintain respiratory-deficient cells.
Histochemical and biochemical analyses of respiratory
chain enzymes. Heart tissue from the left and right ven-
tricles of the probands from families 1 and 2 was obtained at
autopsy (within 2 h of death) and heart transplantation,
respectively. The samples were frozen in isopentane previ-
ously cooled to190°C in liquid nitrogen. Cryostat sections
(8 m) were assayed for succinate dehydrogenase (SDH)
and cytochrome c oxidase (COX) activities (18). In some
cases, sections were dual-stained for both activities.
Respiratory chain enzyme activities were evaluated in
mitochondrial fractions (19) prepared from fresh skeletal
muscle, cardiac samples, and cultured skin fibroblasts from
the proband of family 1 and whole-cell lysates of cultured
skin fibroblasts from the proband of family 2. The activities
of the individual respiratory chain complexes were deter-
mined spectrophotometrically, as previously described (19),
using the matrix marker citrate synthase as a standard.
Molecular genetic analyses. FAMILY 1. Total DNA was
isolated from skeletal muscle, heart (LV), and cultured
myoblasts from the proband and from circulating blood
lymphocytes obtained from his mother, maternal grand-
mother, and a maternal cousin, according to standard
procedures.
FAMILY 2. Total DNA was isolated from skeletal muscle,
heart, circulating lymphocytes, and cultured skin fibroblasts
from the proband and from circulating blood lymphocytes
from 23 family members spanning four generations of this
large pedigree and included affected and nonaffected
individuals.
The sequence of the entire mitochondrial genome in the
Abbreviations and Acronyms
COX  cytochrome c oxidase
HCM  hypertrophic cardiomyopathy
LHON  Leber’s hereditary optic neuropathy
LV  left ventricle or ventricular
mtDNA  mitochondrial deoxyribonucleic acid
mt-tRNAIle  mitochondrial transfer ribonucleic acid
gene for isoleucine
PCR  polymerase chain reaction
RFLP  restriction fragment length polymorphism
SDH  succinate dehydrogenase
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Figure 1. Pedigrees of family 1 (A) and family 2 (B). An arrow indicates the probands in each family. Solid symbols indicate clinically affected individuals, and those tested for the A4300G mitochondrial
deoxyribonucleic acid mutation have an asterisk. In family 1, there is a less extensive family tree, and from the pedigree, either an X-linked or autosomal-recessive pattern of inheritance is possible. However,
there was no clinical or pathologic evidence of Fabry disease in either family.
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patients’ heart DNA samples was determined using 28
M13-tailed oligonucleotide primer pairs (20). Overlapping
polymerase chain reaction (PCR)-amplified fragments were
sequenced with BigDye terminator cycle sequencing chem-
istries on an Applied Biosystems (Foster City, California)
377 automated DNA sequencer. Sequence data were ana-
lyzed using Navigator and Factura software (Applied Bio-
systems) and compared with the revised Cambridge refer-
ence sequence (21).
Quantification of mutated mtDNA. The levels of mu-
tated mtDNA in skeletal muscle, heart, cultured cells, and
circulating lymphocytes from members of both families
were determined by PCR/restriction fragment length poly-
morphism (RFLP) analysis. Two different strategies were
employed. The first, originally described by Casali et al.
(14), was used to determine the amount of mutated
mtDNA in members of family 2. In the second, a 239–base
pair (bp) fragment encompassing the mutation site was
amplified with the forward primer L4084 (positions 4084–
4103) 5-GTCACCAAGACCCTACTTCT-3 and the
reverse mismatch primer H4322 (positions 4322–4302)
5-GGGGGTTTAAGCTCCTATGAT-3 (mismatch
base shown in bold). Samples were subjected to 30 cycles of
amplification with an annealing temperature of 56°C; the
final extension proceeded for 8 min. After the addition of 30
pmol of each primer, 5 Ci (alpha-32P)-deoxy-
cytidinetriphosphate (3,000 Ci/mmol), and 1 U Taq poly-
merase, the PCR reactions were subjected to an additional
cycle of amplification. Labeled products were precipitated
and equal amounts (1,000 to 2,000 counts) digested with 10
U HinfI (Roche Molecular Biochemicals, Lewes, United
Kingdom). Restriction fragments were separated by 12%
nondenaturing polyacrylamide gel electrophoresis, dried
onto a support, and analyzed with ImageQuant software
(Molecular Dynamics, Eugene, Oregon) following exposure
to a PhosphorImager (Molecular Dynamics). The mismatch
primer creates an additional HinfI recognition site in the
PCR product in the presence of the mutation. On digestion,
a single HinfI site in the wild-type product generates
fragments of 180 and 59 bp. The A4300G mutation
generates an additional recognition site cleaving the 180-bp
fragment into two smaller products of 158 and 22 bp.
High-resolution Northern blot analysis. Total cytosolic
RNA was isolated from solid tissues (200 mg; frozen in
liquid nitrogen and ground to a fine powder), cultured
myoblasts, and fibroblasts (1 to 2  106 cells) using Trizol
reagent (Life Technologies). Large RNA species were
precipitated by the addition of 10 mol/l LiCl, allowing
smaller RNAs (5S tRNA) to be precipitated from the
resulting supernatant. Small RNAs (1 g) were denatured
(90°C for 5 min) and separated through a 13%, 8 mol/l
urea denaturing polyacrylamide gel using 1 Tris Borate
Table 1. Echocardiographic Features of Affected Family Members From Families 1 and 2
Subject
No.
Two-Dimensional Echocardiogram
LVWT
Age
(yrs)/Gender
VS
(mm)
PW
(mm)
LVEDD
(mm)
LVESD
(mm)
EF
(%)
Family 1
IV-01 16/M 8 12 55 34 Normal
IV-02 1/M* 11 13 40 36 10
IV-03 5/M* 11 12 57 54 5
IV-04 6/M 9 8 38 24 Normal
Family 2
III-15 45/F 18 13 46 36 Normal
IV-01 34/M 18 11 69 60 10
IV-03 39/F 16 13 47 33 Normal
IV-05 36/M 18 23 47 33 Normal
IV-08 31/F 17 17 40 24 Normal
IV-09 22/M 27 25 52 34 Normal
23 25 16 82 72 17
IV-20 27/M 19 16 49 33 Normal
28 18 13 68 56 40
IV-23 30/M 13 16 52 33 Normal
V-05 18/F 13 15 45 32 Normal
V-07 17/F 13 16 46 33 Normal
V-08 14/M 12 15 46 32 Normal
V-13 10/M 12 7 45 31 Normal
V-14 10/F 12 15 45 32 Normal
V-20 10/F 12 9 46 32 Normal
*Age at time of death. Family 1: The measurements shown for subject nos. IV-01 and IV-04 represent the most recent data,
whereas those for IV-02 and IV-03 were taken on admission during the final illness. Family 2: Two values are given for subject
nos. IV-09 and IV-20, indicating the rapid decline in cardiac function observed in these patients.
LVEDD  left ventricular end-diastolic diameter; LVESD  left ventricular end-systolic diameter; LVWT  left
ventricular wall thickness; PW  posterior wall; VS  ventricular septum; other abbreviations as in Table 1.
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EDTA (TBE) as a running buffer. Separated samples were
electroblotted onto GeneScreen-plus membranes (NEN
Dupont, Steverage, United Kingdom) in 0.25 TBE and
immobilized by ultraviolet cross-linking. Regions of
mtDNA encompassing the tRNAIle and tRNALeu(UUR)
genes amplified by PCR were used as probes for Northern
blots. The mt-tRNAIle probe was amplified using the forward
primer L4152 (positions 4152–4171) 5-CGACCAACT-
CATACACCTCC-3 and the reverse primer H4328 (posi-
tions 4328 – 4308) 5-AAATAAGGGGGTTTAA-
GCTCC-3. The mt-tRNALeu(UUR) probe was amplified
using the forward primer L3200 (positions 3200–3219)
5-TATACCCACACCCACCCAAG-3 and the reverse
primer H3353 (positions 3353–3334) 5-GCGATT-
AGAATGGGTACAAT-3. Purified PCR products
(QIAquick PCR purification columns, Qiagen, Crawley,
United Kingdom) were radiolabeled with (alpha-32P)-
deoxycytidinetriphosphate (3,000 Ci/mmol) by the random-
primer method, and unincorporated nucleotides were removed
by gel filtration through a Sephadex G-50 DNA grade column
(Amersham Pharmacia Biotech, Uppsala, Sweden). Hybrid-
ization was carried out at 42°C overnight in a solution of 5
SSPE, 50% formamide, 10% dextran sulfate, 5 Denhardt’s
solution, and 1% sodium dodecyl sulfate (SDS) containing 2
106 cpm radiolabeled probe. After hybridization, two 15-min
washes were performed at room temperature with 2 SSPE,
followed by a 15-min wash at 65°C with 2 SSPE and 2%
SDS. Blots were subjected to PhosphorImager analysis and the
radioactive signal for the mt-tRNAIle probe (69 bp) normal-
ized to that of the mt-tRNALeu(UUR) probe (75 bp) for each
sample.
Table 2. Clinical Characteristics of Members of Family 2
Subject
No.
Age
(yrs)/Gender
Clinical
Symptoms ECG
Two-Dimensional
Echocardiogram
II-01 90/F None Normal NA
III-01 59/F None TWI NA
III-02 54/F CD NA NA
III-03 56/F Dyspnea LVH, TWI NA
III-04 54/F None TWI NA
III-05 59/M Dyspnea LVH, TWI NA
III-13 48/F None Normal LVH
III-14 46/F None Normal Normal
III-15 45/F Dyspnea, CP LVH, TWI LVH
III-16 33/F CD NA NA
IV-01 34/M NYHA class IV LVH LVH and dilation
IV-02 32/F None Normal Normal
IV-03 39/F Dyspnea LVH, TWI, short
PR interval
LVH
IV-04 37/F None Normal Normal
IV-05 36/M CP LVH LVH
IV-07 26/F None Normal Normal
IV-08 31/F Dyspnea LVH, TWI LVH
IV-09 23/M Dyspnea LVH, TWI LVH and dilation
IV-16 32/F None Normal Normal
IV-20 28/M Dyspnea LVH LVH and dilation
IV-21 25/F None Normal Normal
IV-23 30/M None LVH LVH, PW
IV-24 28/F None Normal Normal
IV-25 23/F None Normal Normal
IV-26 23/F None Normal Normal
IV-27 19/F None Normal Normal
V-01 13/M None Normal Normal
V-02 8/M None Normal Normal
V-03 14/F None Normal Normal
V-04 6/F None Normal Normal
V-05 18/F None NA LVH
V-06 16/F None Normal Normal
V-07 17/F None NA LVH
V-08 14/M Normal NA LVH
V-12 12/F Normal NA Mild AR
V-13 10/M Normal LVH LVH, septal
V-14 10/F Normal LVH LVH
V-20 10/F Normal LVH LVH
The data presented reflect the most recent clinical, electrocardiographic, two-dimensional echocardiogram results.
AR  aortic regurgitation; CD  cardiac death; CP  chest pain; ECG  electrocardiogram; F  female; LVH  left
ventricular hypertrophy; M  male; NA  not applicable; NYHA  New York Heart Association; TWI  T-wave inversion;
PW  posterior wall.
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RESULTS
Histochemical and biochemical analyses of respiratory
chain enzymes. Histologic examination of postmortem
and explanted hearts failed to show significant myofiber
disarray. Histochemical analysis of heart tissue from both
probands revealed large numbers of cells devoid of COX
activity, which was particularly evident when the sections
were dual-stained for both COX and SDH activity. The
number of COX-negative cells was higher in the left than in
the right ventricle (Figs. 2A to D). However, the activities
of both SDH and COX were normal in skeletal muscle
from the proband of family 1, and there were no other
histochemical features suggestive of mitochondrial disease,
such as the subsarcolemmal accumulation of mitochondria
(ragged-red fibers) (Fig. 2E).
The results of the biochemical analysis of respiratory
chain enzyme activities for Patient no. IV-03 of family 1 are
reported in Table 3. There was a severe defect in the
activities of both complexes I and IV in heart mitochondria,
with normal activity of complex II. The activities of indi-
vidual respiratory chain complexes were entirely normal in
the muscle (Table 3) and cultured skin fibroblasts from this
family, as well as in the fibroblasts and MyoD-converted
myoblasts from family 2 (data not shown).
Molecular genetic analysis. SEQUENCE ANALYSIS OF THE
ENTIRE MITOCHONDRIAL GENOME. There was no evi-
dence of mtDNA rearrangements or mtDNA depletion on
Southern blot analysis of DNA from the heart (data not
shown). The sequence of the entire mitochondrial genome
amplified using DNA extracted from both proband hearts
showed, in addition to the A4300G mutation, a number of
neutral polymorphisms (3,22) that were clearly different
between the two families. Consequently, these two families
are certainly unrelated. Surprisingly, family 2 showed 10
sequence changes (A3358T, C6336T, T7657C, A8440G,
G8790A, A13434G, T13500C, A14062G, G14305A,
G14323A) that are not registered on the MITOMAP data
base. The presence of such a large number of sequence
variants in mitochondrial heart DNA prompted us to also
sequence mtDNA from skin fibroblasts, where identical
changes were seen. This confirmed not only that the
A4300G mutation is the only mtDNA defect common to
the two families, but also that a second mitochondrial
mutation was not contributing to the expression of the
cardiac-specific phenotype.
DEMONSTRATION OF HOMOPLASMIC A4300G MUTA-
TION. We assessed the level of the A4300G mutation in all
available DNA samples from both families using PCR-
RFLP analysis. The presence of the mutant G4300 allele
creates an additional recognition site for the restriction
enzyme HinfI, permitting the detection of heteroplasmic
mtDNA at this site. The mutation was homoplasmic in
every tissue investigated from Patient no. IV-03 of family 1
(Fig. 3), with no wild-type mtDNA visible even after
prolonged exposure of the dried gel to the PhosphorImager
Figure 2. Histochemical analysis of skeletal muscle and cardiac tissue. (A)
Age-matched control heart sample dual-stained for cytochrome c oxidase
(COX) and succinate dehydrogense (SDH) activity. (B) Right ventricular
sample from Patient no. IV-03 (family 1) dual-stained for COX and SDH
activity, highlighting the distribution of COX-negative (blue) cells. (C)
Left ventricular sample from Patient no. IV-03 (family 1) dual-stained for
COX and SDH activity. (D) Left ventricular sample from Patient no. IV-01
(family 2) dual-stained for COX and SDH activity. (E) A transverse section of
skeletal muscle from the proband in family 1 (IV-03) reacted for COX activity,
showing a normal staining pattern. The scale bar represents 200 m.
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plate. The 4300G allele was also homoplasmic in blood cells
from the patient’s mother, maternal grandmother, and also
a maternal cousin (data not shown). Our findings in family
1 prompted us to reinvestigate the A4300G mutation in
family 2, previously reported by Casali et al. (14,15) as
heteroplasmic. We screened blood and fibroblast DNA
from 23 maternal relatives by PCR-RFLP analysis (Fig. 1).
The mutation was homoplasmic in every individual, both
symptomatic and asymptomatic, contrary to the earlier
report (15) (Fig. 4, RFLP patterns of three representative
family members shown). This highlights the importance of
using appropriate controls in the analysis of mtDNA mu-
tations (23) and raises concerns about reports of mutations
within single families.
Table 3. Respiratory Chain Complex Activities in Skeletal Muscle Mitochondria and Cardiac
(Left Ventricle) Mitochondria From the Index Case (Patient IV-03) of Family 1
Complex
Skeletal Muscle Cardiac Muscle
Controls
(n  15) Patients
Controls
(n  8) Patients
Complex I/CS 0.240  0.060 0.317 0.254  0.074 0.015
Complex II/CS 0.320  0.088 0.413 0.281  0.036 0.196
Complex IV/CS 1.34  0.39 1.48 2.34  0.54 0.059
Complex I/II 0.74  0.12 0.77 0.88  0.18 0.077
Complex IV/II 4.31  1.36 3.57 8.08  1.90 0.302
Control data are presented as the mean value  SD. Enzyme activities are expressed as nmol NADH oxidized min/U citrate
synthase (CS) for complex I; nmol 2,6-dichlorophenol-indophenol reduced min/U citrate synthase for complex II (succinate:
ubiquinone-1 reductase); and the apparent first-order rate constant.s/U citrate synthase for complex IV (103).
Figure 3. Quantification and distribution of the A4300G mutation in family 1. (A) Scheme of the restriction fragment length polymorphism (RFLP)
analysis performed. A single HinfI site cuts the wild-type polymerase chain reaction-amplified product of 239 bp into two fragments of 180 and 59 bp. In
the presence of the A4300G mutation, a mismatched reverse primer creates a new HinfI recognition site that cuts the 180-bp fragment into two smaller
products of 158 and 22 bp. (B) Labeled products generated by the RFLP analysis were separated through a 12% nondenaturing polyacrylamide gel.
Fragment sizes (bp) are shown on the right. mtDNA  mitochondrial deoxyribonucleic acid.
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DETERMINATION OF STEADY-STATE MT-TRNAILE LEVELS IN
BOTH FAMILIES. To investigate the effect of the A4300G
mutation on the processing of mt-tRNAIle from its precur-
sor, the steady-state level of mt-tRNAIle was determined in
tissues from affected individuals by Northern blot hybrid-
ization. There was a marked decrease (5% to 10% of
controls) in the quantity of the mature mt-tRNAIle tran-
scripts from LV tissue of both probands compared with
Figure 4. Quantification and distribution of the A4300G mutation in family 2. (A) Labeled products generated by the same restriction fragment length
polymorphism (RFLP) analysis described in Figure 3, showing the homoplasmic mutation in the heart deoxyribonucleic acid of both probands (IV-03 in
family 1 and IV-01 in family 2) and in the fibroblasts of the proband (IV-01) from family 2. Fragment sizes (bp) are shown on the right. (B) Scheme of
the alternative RFLP analysis first described by Casali et al. (14). In combination with the A4300G mutation, a mismatched forward primer creates a new
HphI recognition site that cuts the 263-bp polymerase chain reaction-amplified product into two smaller products of 235 and 28 bp. In this assay, wild-type
mitochondrial deoxyribonucleic acid (mtDNA) remains uncut. (C) Representative gel of samples from three family members showing labeled products
generated by the RFLP analysis described earlier. A total of 23 maternal relatives were screened by this assay and shown to be homoplasmic for the A4300G
mutation. Fragment sizes (bp) are shown on the right.
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controls (Fig. 5). However, the mt-tRNAIle gene did not
show any obvious size change in the mutant form. A similar
decrease (10% to 15% of controls) was also observed in
skeletal muscle, a clinically unaffected tissue, from the
proband of family 1, when compared with steady-state levels
of mt-tRNALeu(UUR) in the same samples. Cultured skin
fibroblasts and myoblasts from both families expressed the
molecular defect to a lesser extent (40% and 50% of
control values).
DISCUSSION
We have described the detailed clinical, histochemical,
biochemical, and molecular genetic investigation of two
families with maternally inherited HCM that revealed a
homoplasmic mutation in the mt-tRNAIle gene. The mu-
tation affects a base pair in the secondary structure of
mt-tRNAIle in a region of the gene that shows high
evolutionary conservation. The clinical features of this
cardiomyopathy are distinct from those of familial
autosomal-dominant HCM. All affected patients from both
families presented with nonobstructive HCM without
symptoms of other system dysfunction. There was a
mildly asymmetric pattern of LV hypertrophy, with some
patients showing a prominent thickening of the posterior
wall and others of the ventricular septum (Table 1).
The illness often had an adverse clinical course, with
LV dilation and failure, even at a young age. There were
two childhood deaths in family 1 and two deceased mem-
bers, a heart transplant recipient at age 34 years and a
23-year-old patient with heart failure waiting for heart
transplant in family 2. An additional member of family 2
(Patient no. IV-20) with a LV cavity size within the upper
normal limits, showed LV dilation and decreased ejection
fraction on a six-month follow-up echocardiogram (Table
1). Although rapidly evolving cardiac failure was observed,
neither ventricular arrhythmias nor sudden death were
noted in these families.
Numerous heteroplasmic point mutations within mt-
tRNA genes have been reported as causing disease, several
in association with a number of cardiac muscle disorders
(12,13). These include pathologic changes at A4317G (24),
C4320T (25), A4295G (26), and A4269G (27) within the
mt-tRNAIle gene. Although the A4300G mutation was
initially judged to be heteroplasmic when first described
(14), our present studies of these two families not only
confirm the importance of the mt-tRNAIle gene as a
“hot spot” for mitochondrial cardiomyopathy mutations,
but also highlight the role that homoplasmic mt-tRNA
mutations can play in causing isolated cardiomyopathy. This
has important implications for the diagnosis of these con-
ditions. For example, homoplasmic mutations in mtDNA
previously reported as neutral polymorphisms could be
pathogenic, especially if associated with tissue-specific dis-
orders.
The results of our biochemical and molecular studies in
these two families strongly support the pathogenic role of
the homoplasmic A4300G mtDNA transition. There were
very low activities of respiratory chain complexes I and IV
(both contain mitochondrially encoded polypeptide sub-
units) in heart tissue and a marked decrease in the amount
of mature cardiac mt-tRNAIle (10% of controls). Surpris-
ingly, comparably low steady-state levels of mt-tRNAIle
were also observed in skeletal muscle, even though only the
heart was biochemically and clinically affected. The presence
of additional local factors, such as ventricular hemodynamic
load or expression of cardiac-specific genes, acting indepen-
dently or synergistically with the homoplasmic mtDNA
mutation could explain the difference in phenotypic expres-
sion between cardiac and skeletal muscle. The finding of a
marked difference in histochemical COX activity, even
between the left and right ventricles, reinforces this hypoth-
esis. The expression of several cardiac genes may vary
between the left and right ventricles, both in normal
conditions and in response to differences in load and local
stress (28–30). The energy demands placed on the LV are
much greater than those placed on the right ventricle, and
the severity of the mitochondrial defect in the LV of these
hearts would be sufficient to cause heart failure.
Homoplasmic mtDNA mutations present many chal-
lenges in understanding the molecular mechanism of dis-
ease, particularly as they predominantly appear to present in
a tissue-specific manner—for example, LHON (6) and
sensorineural deafness (8,9). The former is a mitochondrial
DNA disorder in which the vast majority of patients present
solely with optic neuropathy. The other feature in common
between patients with LHON mutations and our families is
that in both there was a very sudden onset of symptoms. In
LHON, this presents with acute or subacute visual loss and
in our patients with cardiac failure. Although it seems likely
that the cause of the acute symptoms is an energy crisis in
specific tissues, dissecting out the important genetic and
environmental factors in LHON has proved extremely
difficult. In some patients with sensorineural deafness, there
is a clear association between a point mutation (A1555G) in
the 12S mt-rRNA gene and toxicity to aminoglycosides (8),
an obvious environmental factor. Such a situation, however,
is not evident in our patients or in the majority of families
with LHON.
Conclusions. Our extensive studies of these families have
confirmed that the A4300G mutation is causative because
of the mitochondrial biochemical defects in the affected
tissue. Although rare compared with heteroplasmic changes,
pathogenic, homoplasmic mtDNA mutations have been
reported previously in association with various tissue-
specific presentations, in particular the optic nerve in pa-
tients with LHON and sensorineural deafness (8,11). We
believe that in individual patients, similar homoplasmic
changes are not being pursued as potential causes of disease
because either we do not recognize a particular phenotype or
the mtDNA change seen was found to be homoplasmic and
thus thought unlikely to be pathogenic. On this basis, it is
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Figure 5. Determination of steady-state mitochondrial transfer ribonucleic acid gene for isoleucine (mt-tRNAIle) levels in solid tissues and cultured cells
using high-resolution Northern blots. Small ribonucleic acids (1 g) were separated through a 13%, 8 mol/l urea denaturing polyacrylamide gel,
electroblotted onto membranes and hybridized with radiolabeled probes specific for mt-tRNAIle and mt-tRNALeu(UUR) transcripts as described in Methods:
High-resolution Northern blot analysis. Together with the patient samples, each panel shows three appropriate control samples prepared from the identical
tissue or cell type. (A) Left ventricle of Patient no. IV-03 (family 1). (B) Skeletal muscle of Patient no. IV-03 (family 1). (C) Left ventricle of Patient no.
IV-01 (family 2). (D) Cultured myoblasts of Patient no. IV-03 (family 1). (E) Cultured skin fibroblasts of patient no. IV-03 (family 1; lane 1), Patient
no. IV-01 (family 2; lane 2), and Patient no. IV-03 (family 2; lane 3).
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possible that homoplasmic mt-tRNA mutations are greatly
under-reported as causes of mitochondrial disorders (31),
and they may play a more important role in the development
of cardiomyopathy than previously thought.
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